TRCT
AVDL

Tower Research Capital (TRC)’s Avadel Pharmaceuticals AVDL Stock Holding History

Tower Research Capital (TRC)’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,160
Closed -$499K – 5126
2025
Q4 		$499K Buy
23,160
+21,679
+1,464% +$421K 0.01% 831
2025
Q3 		$22.6K Sell
1,481
-7,314
-83% -$95.2K ﹤0.01% 3201
2025
Q2 		$77.8K Buy
8,795
+6,025
+218% +$52.9K ﹤0.01% 2590
2025
Q1 		$21.7K Buy
2,770
+1,571
+131% +$13.2K ﹤0.01% 2889
2024
Q4 		$12.6K Sell
1,199
-9,301
-89% -$113K ﹤0.01% 3604
2024
Q3 		$138K Sell
10,500
-20,179
-66% -$307K ﹤0.01% 1965
2024
Q2 		$431K Buy
30,679
+29,847
+3,587% +$487K 0.01% 1461
2024
Q1 		$14.1K Sell
832
-1,740
-68% -$25.9K ﹤0.01% 3343
2023
Q4 		$36.3K Sell
2,572
-11,945
-82% -$140K ﹤0.01% 3323
2023
Q3 		$150K Buy
14,517
+9,707
+202% +$130K ﹤0.01% 1662
2023
Q2 		$79.3K Buy
4,810
+956
+25% +$12.4K ﹤0.01% 2221
2023
Q1 		$35K Sell
3,854
-2,396
-38% -$19.7K ﹤0.01% 2831
2022
Q4 		$45K Sell
6,250
-8,114
-56% -$56.9K ﹤0.01% 2426
2022
Q3 		$72K Buy
14,364
+10,097
+237% +$55.6K ﹤0.01% 2846
2022
Q2 		$10K Buy
4,267
+76
+2% +$312 ﹤0.01% 4428
2022
Q1 		$29K Sell
4,191
-15,579
-79% -$107K ﹤0.01% 3173
2021
Q4 		$159K Buy
19,770
+13,688
+225% +$125K ﹤0.01% 1928
2021
Q3 		$60K Sell
6,082
-2,415
-28% -$19K ﹤0.01% 2804
2021
Q2 		$58K Buy
8,497
+5,530
+186% +$43.9K ﹤0.01% 2900
2021
Q1 		$27K Sell
2,967
-12,279
-81% -$99.3K ﹤0.01% 3632
2020
Q4 		$102K Buy
15,246
+4,309
+39% +$26.9K ﹤0.01% 2326
2020
Q3 		$55K Buy
+10,937
New +$79.6K ﹤0.01% 3495
2019
Q4 		– Sell
-765
Closed -$3K – 3518
2019
Q3 		$3K Sell
765
-1,849
-71% -$4.63K ﹤0.01% 3522
2019
Q2 		$8K Buy
2,614
+2,456
+1,554% +$4.22K ﹤0.01% 2671
2019
Q1 		$0 Sell
158
-18
-10% -$41 ﹤0.01% 3775
2018
Q4 		$0 Buy
+176
New +$598 ﹤0.01% 3811
2018
Q2 		– Sell
-9,740
Closed -$71K – 3626
2018
Q1 		$71K Buy
9,740
+9,557
+5,222% +$84.1K 0.01% 1470
2017
Q4 		$2K Sell
183
-3,003
-94% -$28.2K ﹤0.01% 3178
2017
Q3 		$33K Sell
3,186
-1,407
-31% -$13.4K ﹤0.01% 2342
2017
Q2 		$51K Buy
4,593
+4,336
+1,687% +$43.5K 0.01% 740
2017
Q1 		$2K Sell
257
-497
-66% -$4.97K ﹤0.01% 2589
2016
Q4 		$8K Sell
754
-889
-54% -$9.77K ﹤0.01% 2763
2016
Q3 		$20K Buy
1,643
+919
+127% +$12K ﹤0.01% 1609
2016
Q2 		$7K Buy
+724
New +$7.72K ﹤0.01% 3106
2016
Q1 		– Sell
-1,689
Closed -$21K – 4095
2015
Q4 		$21K Sell
1,689
-3,386
-67% -$52.8K ﹤0.01% 1236
2015
Q3 		$83K Buy
5,075
+4,634
+1,051% +$102K 0.01% 669
2015
Q2 		$9K Buy
+441
New +$7.91K ﹤0.01% 2774
2015
Q1 		– Sell
-2,936
Closed -$50K – 4389
2014
Q4 		$50K Buy
2,936
+2,836
+2,836% +$40.5K ﹤0.01% 1033
2014
Q3 		$1K Sell
100
-537
-84% -$7.72K ﹤0.01% 4043
2014
Q2 		$10K Buy
637
+537
+537% +$6.48K ﹤0.01% 2341
2014
Q1 		$1K Buy
+100
New +$1.07K ﹤0.01% 4105
2013
Q4 		– Sell
-1,155
Closed -$8K – 4444
2013
Q3 		$8K Sell
1,155
-225
-16% -$1.38K ﹤0.01% 3335
2013
Q2 		$8K Buy
+1,380
New +$7.13K ﹤0.01% 2550

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Tower Research Capital (TRC)'s AVDL Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 23,160 shares — an estimated $499K sold.

Tower Research Capital (TRC) first reported a position in AVDL in Q2 2013 and held it in 43 quarters. The position peaked at $499K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 23,160 Avadel Pharmaceuticals shares in Q1 2026, an estimated $499K.
  • Tower Research Capital (TRC) first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • Tower Research Capital (TRC)'s Avadel Pharmaceuticals position peaked at $499K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.